Log In

 

All News


Sort By News Date & Time Sort Descending Order News Source News Title

  Refine Search  
Keywords
Date Range
 
News Type
  India
  International

07/06/2017 5:50PM

AstraZeneca Presents Tagrisso (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases

AstraZeneca reported further evidence that Tagrisso (osimertinib), the potential new standard of care for adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M ...

17/10/2017 10:45AM

AstraZeneca and Chi-Med's Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification

AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials ...

14/10/2017 11:05AM

FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1

AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Faslodex (fulvestrant) that ...

06/12/2016 9:59AM

Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukaemia

AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms ...

13/12/2017 9:20AM

AstraZeneca's Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ...

20/11/2017 9:15AM

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer

AstraZeneca announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of ...

20/11/2017 9:30AM

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases

AstraZeneca presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor ...

17/11/2017 6:05PM

AstraZeneca to Present Transformative Data at ESMO Asia 2017 Congress from Pivotal Trials Showing Potential New Standards of Care in Non-small Cell Lung Cancer

At the ESMO Asia 2017 Congress in Singapore, 17-19 November 2017, AstraZeneca and MedImmune, its global biologics research and development arm, will share ground-breaking results from two pivotal trials, as well as new ...